FierceBiotech5d
Boehringer's phase 3 lung fibrosis trial hits primary endpoint, teeing up filings for Ofev successor
Boehringer Ingelheim has ended a decade of industrywide failures in idiopathic pulmonary fibrosis (IPF) by reporting a phase ...
Boehringer Ingelheim faces second hung jury in Chicago Zantac trial
The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, ...
ENDPOINTS NEWS5d
Boehringer plans NDA fil­ing for pul­monary fi­bro­sis drug fol­low­ing Phase 3 da­ta
A Phase 3 trial investigating Boehringer Ingelheim’s nerandomilast in idiopathic pulmonary fibrosis hit its primary endpoint, ...
GlobalData on MSN11d
Boehringer Ingelheim reports positive results from trial of HER2 lung cancer drug
The trial met its primary endpoint, showing a meaningful objective response rate and a tolerable safety profile for ...
BioWorld2d
Boehringer Ingelheim divulges new NOX4 inhibitors
Boehringer Ingelheim Pharma GmbH & Co. KG has synthesized NADPH oxidase 4 (NOX4) inhibitors reported to be useful for the treatment of atherosclerosis, cancer, pulmonary hypertension, inflammatory ...
GlobalData on MSN5d
Boehringer seeks approval for lung fibrosis drug following Phase III win
The Phase III trial evaluating nerandomilast as a treatment for idiopathic pulmonary fibrosis met its primary endpoint.
Business Insider5d
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
1,5 Full efficacy and safety data from the trial will be presented in the first half of 2025. Boehringer Ingelheim will submit a new drug application for nerandomilast for the treatment of IPF to the ...